Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-naphthyl-1-acetamido boronic acid alanine is a synthetic small molecule belonging to the class of naphthalene derivatives. It functions as a transition-state analog inhibitor of serine proteases, specifically designed to mimic the tetrahedral intermediate formed during peptide bond hydrolysis. This compound has been studied primarily in biochemical and structural biology research as an experimental inhibitor for enzymes such as subtilisin Carlsberg and gamma-chymotrypsin. The D-enantiomer, in particular, exhibits unique binding properties compared to its L-counterpart, forming covalent adducts with the catalytic serine residue of target proteases[4][9]. There are no approved therapeutic indications or clinical uses for this compound; it is used exclusively in experimental settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d-naphthyl-1-acetamido boronic acid alanine.